Authors

Latest:

The Importance of Curiosity in Expanding Cancer Immunology

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Jill Stein

Latest:

Nab-Paclitaxel Boosts Survival in Pancreatic Cancer

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

Jim C. Hu, MD

Latest:

Dr. Hu on the Increase in Incidence of Advanced Prostate Cancer

Jim C. Hu, MD, professor of Urology, Weill Cornell Medical College, discusses the increase in the incidence of advanced prostate cancer in the United States.

Jim Feldman

Latest:

Jim Feldman on the Importance of Social Networking for Urologists

Jim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.

Jim Hu, MD, MPH

Latest:

Dr. Hu on Active Surveillance for Prostate Cancer

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.

Jim M. Koeller, MS FHOPA

Latest:

Explaining the Variability of Biologics and Biosimilars

Jim M. Koeller, MS, FHOPA, discusses the inherent variability of recombinant DNA technology behind biosimilars.

Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.

Latest:

Impact of Trilaciclib on the Treatment Landscape

Ralph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.

Jimmie C. Holland, MD

Latest:

Dr. Holland on the Stigma Toward Psychosocial Care

Dr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.

Jimmy J. Caudell, MD, PhD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Jing Ai, MD

Latest:

Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

Jing Zeng, MD

Latest:

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Jing-Zhou Hou, MD, PhD

Latest:

Dr. Hou on Polatuzumab Vedotin in DLBCL

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).

Jingsong Zhang, MD, PhD

Latest:

Dr. Zhang on the State of Risk Stratification in mCRPC

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

Jivesh Sharma, MD

Latest:

Opportunities and Challenges: A Time to Reflect at the End of a Busy Year

It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.

Jo Anne Zujewski, MD

Latest:

Dr. Zujewski Discusses Breast Cancer Drug Development

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.

Joachim G. Aerts, MD, PhD, Erasmus Medical Center Cancer Institute

Joan Lunden

Latest:

Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

Joan Such Lockhart, PhD, RN, AOCN, FAAN

Latest:

Joan Lockhart on Fostering Oncology Nursing Education

Joan Such Lockhart, PhD, RN, AOCN, FAAN, from the Duquesne University School of Nursing, discusses resources currently available to help strengthen the oncology training of nurses.

Joanna L. Morales, Esq

Latest:

Joanna Morales on Common Cancer Related Legal Issues

Joanna Morales from the Cancer Legal Resource Center on Common Cancer Related Legal Issues

Joanne Blum, MD, PhD

Latest:

Dr. Blum on Takeaways from ABC Trials for Breast Cancer

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.